ClinicalTrials.gg
CompletedNCT03761004Updated Feb 13, 2020

WD-1603 PK Study in Healthy Volunteers

A Phase 1 interventional study of carbidopa-levodopa in Healthy Volunteers, sponsored by Hong Kong WD Pharmaceutical Co., Limited. Completed at 1 site in Canada. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-13.

Sponsored by Hong Kong WD Pharmaceutical Co., Limited · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2019, 7 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a pilot study to investigate if the extended release formulation of WD-1603 generates anticipated plasma concentration profile. The study is an open-label, sequential, 3-way crossover study to evaluate if WD-1603 generates anticipated plasma levodopa exposure compared to Sinemet IR tablets in healthy subjects. The study comprises of a medical Screening visit, three 2-night (3-day) Treatment periods, 2 outpatient visits, and a Follow-up visit. Study drug administration in each Treatment period is separated by a washout interval of 5 days. The Follow-up visit will occur approximately 7 days (±1) following the last study drug administration. The duration of subject participation, including screening, is approximately 6 weeks.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Hong Kong WD Pharmaceutical Co., Limited is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adult male or female subjects, 18 to 55 years of age, inclusive, at the time of signing the form (ICF).
  2. A minimum body weight of 50.0 kg (110.0 lbs) and (BMI) between 18.0 and 30.0 kg/m2, inclusive, at screening.
  3. Non-smoker for at least 3 months and tests negative on urine cotinine test.
  4. Medically healthy subjects with clinically insignificant screening and Day -1 admission results (medical history, 12-lead (ECG), physical examination, vital signs, and laboratory tests) as determined by the Investigator or designee.
  5. Female subjects of with male sexual partners must be using and willing to continue using medically acceptable (true abstinence, hormonal contraceptives [combined oral pill, patch, or vaginal ring], intrauterine device, or double-barrier methods [condom with spermicide, diaphragm or cervical cap with spermicide]) from Screening (or at least 3 months prior to Screening for hormonal contraceptives) until at least 28 days after the last study drug administration.
  6. Female subjects of non-childbearing potential must be either (post-menopausal is defined as being amenorrheic for at least 1 year without another cause and a follicle-stimulating hormone [FSH] level ≥26 IU/L) or surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral tubal ligation).
  7. Male subjects with female sexual partners of childbearing potential must be using and willing to continue using medically acceptable contraception (true abstinence, vasectomy, or male condom for subjects plus an additional method of contraception for their female partners) from Screening until 28 days following the last administration of study drug.
  8. Subjects are able to understand English and to give their signed informed consent before any study-related procedures are performed.

Exclusion criteria

Exclusion Criteria:

  1. History of serious allergic reaction or to levodopa or carbidopa.
  2. Subjects with, or a history of, narrow-angle glaucoma, cancer, diabetes, or any cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, hematologic, dermatological, neurological, psychiatric, or other major disorder.
  3. History of clinically significant drug and/or food allergies as determined by the Investigator or designee, or previous status asthmaticus.
  4. Subject is not willing to abstain from alcohol for 48 hours prior to admission in Day-1 until the final blood draw is complete through the final day of blood draws.
  5. Use of prescription or non-prescription drugs, including herbal and dietary supplements, within 7 days prior to the first dose of study medication.
  6. Treatment with an drug within 30 days prior to the first dosing, or more than 5 half-lives of the compound which the subject was treated with , whichever is longer.
  7. Donation or loss of more than 500 mL whole blood within 30 days preceding the first dose. Subjects must not donate blood or plasma during the study and for at least 56 days after the Follow-up visit.
  8. Difficulty with venous access or unsuitable or unwilling to undergo catheter insertion.
  9. Self-reported substance or alcohol dependence (excluding nicotine and caffeine) within the past 2 years prior to dosing, and/or has ever participated or plans to participate in a substance or alcohol rehabilitation program to treat their substance or alcohol dependence.
  10. Typical weekly alcohol consumption of 14 alcoholic drinks. One standard alcoholic drink is equivalent to 43 mL (1.5 oz.) hard liquor or 142 mL (5 oz.) wine or 341 mL (12 oz.) beer.
  11. Positive results in any of the serology tests of (HIV) and and C infections.
  12. Female subjects who are currently pregnant (have a positive pregnancy test) or lactating or who are planning to become pregnant within 30 days of the last study drug administration.
  13. Positive urine drug at Screening and Day -1 admission. Given the long half-life of tetrahydrocannabinol (THC) and its metabolites, subjects with a positive result for THC at Screening may be included at the discretion of the investigator.
  14. Positive breath alcohol test. Subjects with a positive result at Screening may be rescheduled at the investigator's discretion.
  15. Any condition that, in the opinion of the Investigator or designee, would complicate or compromise the study or the well-being of the subject.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    WD-1603 single dose

    WD-1603 single dose: A single WD-1603 tablet after breakfast. Plasma samples for PK analysis will be collected at pre-dose (baseline) and 10 min, 30 min, 45 min and 1, 1.5, 2, 3, 4, 5, 5.5, 6, 7, 8, 10, 12, 16 and 24 hours post-dose.

    Drug: carbidopa-levodopa

  • Experimental
    WD-1603 BID dose

    WD-1603 BID dose: A single WD-1603 tablet after breakfast, and a second WD-1603 tablet approximately 3 hours after completing lunch. Plasma samples for PK analysis will be collected at pre-dose (baseline) and 10 min, 30 min, 45 min and 1, 1.5, 2, 3, 4, 4.5, 5, 6, 7, 7.25, 7.5, 7.75, 8, 8.5, 9, 10, 10.5 11, 12, 16 and 24 hours post-dose.

    Drug: carbidopa-levodopa

  • Active comparator
    Sinemet single dose

    Sinemet single dose: A single oral dose of Sinemet after breakfast. Plasma samples for PK analysis will be collected at pre-dose (baseline) and 10 min, 30 min, 45 min and 1, 1.5, 2, 3, 4, 6, 7, 8, 10, 12, 16 and 24 hours post-dose.

    Drug: carbidopa-levodopa

Interventions

  • Drugcarbidopa-levodopa

    single dose of WD-1603, BID dose of WD-1603 and Sinemet IR

06

What researchers measure

Primary outcomes

  1. Cmax

    the maximum plasma concentrations

    Time frame: pre-dose(baseline)and specified time points up to 24 hours post-dose(as specified in the Arm/Group description)

  2. AUC0-t

    the areas under the plasma concentration versus time curve calculated from 0 to the last measurable observation

    Time frame: pre-dose(baseline)and specified time points up to 24 hours post-dose(as specified in the Arm/Group description)

  3. AUC0-inf

    the areas under the plasma concentration versus time curve extrapolated from 0 to infinity

    Time frame: pre-dose(baseline)and specified time points up to 24 hours post-dose(as specified in the Arm/Group description)

07

Study locations

1 site
  • INC Research Toronto, Inc.
    Toronto, Canada
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2019 to primary completion in Sep 2019, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2018
First posted
Dec 3, 2018
StartActual
Jan 14, 2019
Primary completionActual
Sep 5, 2019
CompletionActual
Sep 5, 2019
Last update
Feb 13, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03761004
Lead sponsor
Hong Kong WD Pharmaceutical Co., Limited
Responsible party
Sponsor
First posted
Dec 3, 2018
Start date
Jan 14, 2019
Primary completion
Sep 5, 2019
Completion
Sep 5, 2019
Last update
Feb 13, 2020

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion